News

Francisco Guarner: ”We need bacteria to maintain a good immune system”

The first organisms those were able to obtain energy through inorganic matter and sunlight appered on Earth more than 3,500 million years ago. These were the cyanobacteria. Currently, there are still cyanobacteria that perform a similar function. The 20% of the total CO2 is fixed by cyanobacteria, being able to transform inorganic matter to organic. […]

Leer más about Francisco Guarner: ”We need bacteria to maintain a good immune system”

A simple test can prevent colon cancer hereditary

Hereditary colon cancer is a disease that can be prevented successfully with proper monitoring. Lynch syndrome or colon hereditary nonpolyposis colorectal cancernis the most common inherited form, between 1% and 3% of all cases. A simple test within the tumor in all patients with colorectal cancer is better than any clinical recommendation to identify cases […]

Leer más about A simple test can prevent colon cancer hereditary

Jose María Martínez Sánchez, Extraordinary Doctorate Award by UB

The University of Barcelona has granted a special award of the PhD thesis: “Exposure to environmental smoke snuff and tobacco control measures”, by Jose Maria Martinez Sanchez, a postdoctoral researcher IDIBELL-ICO. The thesis, headed by Esteve Fernández, group leader of Cancer Control and Prevention from IDIBELL-ICO is a compendium of seven scientific papers on passive […]

Leer más about Jose María Martínez Sánchez, Extraordinary Doctorate Award by UB

IDIBELL and ICFO researchers have developed a technology that predicts metastasis in breast cancer

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and The Institute of Photonic Sciences (ICFO) have collaborated on the development of a diagnostic tool that identifies the metastatic ability of breast cancer cells. The analysis is based on the characterization of the lipid component of the cells, which is indicative of malignancy. This has allowed […]

Leer más about IDIBELL and ICFO researchers have developed a technology that predicts metastasis in breast cancer

Eva Pros, UB PhD Extraordinary Award

The thesis of Eva Pros, from the Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute of Oncology (ICO), has been awarded with the Extraordinary Doctorate from the University of Barcelona among the theses defended in the Faculty of Biology during the 2010-2011 course. The thesis, entitled “Neurofibromatosi de tipus 1: Anàlisi de mutacions que […]

Leer más about Eva Pros, UB PhD Extraordinary Award

An epigenetic difference in twins could explain the different risk of breast cancer

Monozygotic twins have the same genome, that is, the same DNA molecule in both siblings. Despite being genetically identical, both twins may have different diseases at different times. This phenomenon is called “twin discordance”. But how can people who have the same genetic sequence present different pathologies and at different ages? The explanation partly lies […]

Leer más about An epigenetic difference in twins could explain the different risk of breast cancer

Matias Hidalgo: ”The ciliated cells of inner ear can be regenerated in birds”

The past IDIBELL Seminar from October 5th, entitled “Differentiation of sensory elements of vertebrates inner ear: growth factors and regeneration”, was given by Dr. Matías Hidalgo Sánchez, Doctor of Biology at the University of Extremadura. The conference was held in the Auditorium of the University of Barcelona (Campus Bellvitge). The inner ear consists of a […]

Leer más about Matias Hidalgo: ”The ciliated cells of inner ear can be regenerated in birds”

IDIBELL and ICO researchers, awarded by the Children’s Tumor Foundation

The selected project is entitled “Targeting NF‐1 associated MPNST with aurora kinase inhibitors” and is awarded with the maximum compensation in their category, with $50,000. It is intended for the use of aurora kinase inhibitors to treat animal models generated in the ICO and IDIBELL premises.

Leer más about IDIBELL and ICO researchers, awarded by the Children’s Tumor Foundation
Scroll to Top